Silver Book Fact

In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2 years after.

Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis. Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs. Parkinsonism & Related Disorders. 2004; 10(8): 475-9. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15542007&dopt=AbstractPlus

Reference

Title
Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs
Publication
Parkinsonism & Related Disorders
Publication Date
2004
Authors
Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis
Volume & Issue
Volume 10, Issue 8
Pages
475-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 out-of-pocket costs to individuals and families dealing with the…  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050